Vitamin D Therapy to Reduce Cardiac Damage Among Vulnerable Hypertensive Patients
- Conditions
- HypertensionLeft Ventricular Hypertrophy
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: cholecalciferol (Vitamin D)
- Registration Number
- NCT01360476
- Lead Sponsor
- Wayne State University
- Brief Summary
This project seeks to reduce the disparity in hypertensive heart disease which exists for African-Americans who have poorly controlled hypertension (HTN), also known as blood pressure (BP). The investigators are targeting a highly vulnerable, often neglected subject population which stands to benefit tremendously from better BP control and a corresponding decrease in heart damage. HTN occurs early in life and more often in African-Americans, reducing both quality and quantity of life. Inner-city African-Americans with HTN utilize the emergency department (ED) for chronic BP management. Like cardiovascular disease, vitamin D deficiency disproportionately affects African-Americans. Vitamin D is thought to play an important role in cardiovascular health. Vitamin D replacement in those who are deficient has been thought to reduce the cardiovascular disease, especially if initiated early before irreversible damage has occurred, but this has yet to be tested in a prospective clinical trial. Accordingly, this proposal was designed to investigate the relationship between vitamin D and cardiac damage (as identified on cardiac magnetic resonance imaging) in a cohort of African-American, vitamin D deficient hypertensive patients without prior history of heart disease.
The primary objective of this proposal is to evaluate the efficacy of vitamin D therapy in vitamin D deficient African-Americans with HTN. Vitamin D is an inexpensive treatment, which, if shown to be effective could improve the existing approach to a widely accessible, cost-effective option.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 354
- Individuals with known HTN
- African-American race (self reported)
- Repeat SBP ≥ 160 mmHg within 1 hour of arrival
- Age 30-74 years
- Asymptomatic state (class I as defined by Goldman Specific Activity Scale)
- Dyspnea (exertional, rest or nocturnal) or chest pain as a primary or secondary chief complaint
- Prior history of HF, coronary artery disease, myocardial infarction, cardiomyopathy (any), valvular heart disease (any) or renal failure with current, previous, or planned future dialysis
- Acute illness or injury which necessitates hospital admission
- Acute alcohol or cocaine intoxication or history of chronic alcohol (determined using the CAGE screening questions) or cocaine (self-reported) abuse
- Acute or decompensated psychiatric disorder or any underlying psychiatric disorder or cognitive deficit which precludes effective on-going communication or ability to follow-up as required
- Cancer (other than skin), HIV, or any other medical condition that might limit life expectancy
- Hepatitis or liver enzyme (ALT, AST) elevations > 1.5x normal
- Planned move > 50 miles in the next 9 months
- History of kidney stones
- GFR <30
- Serum calcium > 10.5 mg/dl or known history of hypercalcemia
- History of or known primary hyperparathyroidism
- Sarcoidosis or other granulomatous disease
- Pregnant or planning to become pregnant
- Allergy or known hypersensitivity to gadolinium contrast
- Severe claustrophobia
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description placebo Placebo - Vitamin D cholecalciferol (Vitamin D) -
- Primary Outcome Measures
Name Time Method Change from Baseline in left ventricular hypertrophy at 1 year baseline, 16weeks, 52weeks Cardiac MRI will be used to assess this change.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Detroit Receiving Hospital
🇺🇸Detroit, Michigan, United States